AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31828172 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi pollen capsules (SPCs)
Number of subjects: 288
Study 28941598 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT) - 4 minutes at 80% VO2peak followed by 3 minutes at 50% VO2peak, 4 weeks, 400 kcal/session
Number of subjects: 18
Study 28941598 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Exercise Training (MICT) - 55% VO2peak, 60 minutes, 4 weeks, 400 kcal/session
Number of subjects: 18
Study 28941598 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 18
Study 27219884 — intervention group
Group type: EXPERIMENTAL
Intervention: HUCMSC transplantation after angioplasty
Number of subjects: 53
Study 27219884 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty (Control)
Number of subjects: 53
Study 24844538 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy with Amniotic Membrane Transplant (AMT)
Number of subjects: 52
Study 24844538 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy with Mitomycin-C (MMC)
Number of subjects: 52
Study 24844538 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic Membrane Transplant (AMT)
Number of subjects: 52
Study 24844538 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin-C (MMC)
Number of subjects: 52
Study 22335885 — intervention group
Group type: EXPERIMENTAL
Intervention: Splinting
Number of subjects: 52
Study 19062223 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided (US) technique
Number of subjects: 66
Study 19062223 — intervention group
Group type: COMPARATOR
Intervention: Standard landmark (LM) technique
Number of subjects: 66
Study 18332764 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate placement condition (46 implants)
Number of subjects: 64
Study 18332764 — intervention group
Group type: COMPARATOR
Intervention: Delayed placement condition (36 implants)
Number of subjects: 64
Study 15726322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative tissue samples
Number of subjects: 63
Study 15726322 — intervention group
Group type: COMPARATOR
Intervention: Swab samples
Number of subjects: 63
Study 15726322 — intervention group
Group type: COMPARATOR
Intervention: Patients receiving systemic antimicrobial treatment
Number of subjects: 63
Study 15726322 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without prior antibiotic treatment
Number of subjects: 63
Study 12904977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium augmentation therapy
Number of subjects: 803
Study 12904977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 803
Study 10499943 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice based on the Ottawa Knee Rule
Number of subjects: 0
Study 10499943 — intervention group
Group type: COMPARATOR
Intervention: Usual practice based on physician judgment
Number of subjects: 0
Study 8932071 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 units heparin/ml saline (HS)
Number of subjects: 118
Study 8932071 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 118
Study 1859059 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (100 micrograms/puff, three times two puffs)
Number of subjects: 36
Study 1859059 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three times two puffs)
Number of subjects: 36
Study 6378117 — intervention group
Group type: EXPERIMENTAL
Intervention: Active medication
Number of subjects: 185
Study 6378117 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 185
Study 30221961 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care intervention (removal from institutions and placement into a family)
Number of subjects: 0
Study 30221961 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (remaining in institutions)
Number of subjects: 0
Study 29018897 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol dose escalation
Number of subjects: 0
Study 29018897 — intervention group
Group type: EXPERIMENTAL
Intervention: Urate addition in RAW264.7 cell osteoclastogenesis assay
Number of subjects: 0
Study 29018897 — intervention group
Group type: EXPERIMENTAL
Intervention: Urate addition in primary cell osteoclastogenesis or resorption assays
Number of subjects: 0
Study 29018897 — intervention group
Group type: EXPERIMENTAL
Intervention: Urate addition in MC3T3‐E1 pre‐osteoblast, primary human osteoblast, or MLO‐Y4 osteocyte assays
Number of subjects: 0
Study 27206549 — intervention group
Group type: EXPERIMENTAL
Intervention: Arabinoxylan-oligosaccharide (AXOS) 4 × 9.4 g
Number of subjects: 13
Study 27206549 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (placebo) 4 × 10 g
Number of subjects: 13
Study 24529258 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (24 schools, 1,222 pupils)
Number of subjects: 1939
Study 24529258 — intervention group
Group type: COMPARATOR
Intervention: Control group (14 schools, 717 pupils)
Number of subjects: 1939
Study 24529258 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish consumption
Number of subjects: 1939
Study 24529258 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-food consumption
Number of subjects: 1939
Study 19104205 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerin payayor, a Thai prepared herbal product, used 3 times a day from the first to the last day of radiation.
Number of subjects: 60
Study 19104205 — intervention group
Group type: COMPARATOR
Intervention: Benzydamine hydrochloride, rinsed 3 times a day from the first to the last day of radiation.
Number of subjects: 60
Study 16398424 — intervention group
Group type: EXPERIMENTAL
Intervention: Sijunzi decoction (SJZD)
Number of subjects: 92
Study 16398424 — intervention group
Group type: COMPARATOR
Intervention: Control group (isocaloric and isonitrogenous enteral nutritional support only)
Number of subjects: 92
Study 11756368 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical abortion (mifepristone 200 mg followed by misoprostol up to 3 doses)
Number of subjects: 188
Study 11756368 — intervention group
Group type: COMPARATOR
Intervention: Surgical abortion (vacuum aspiration under general anaesthesia)
Number of subjects: 188
Study 11756368 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical abortion
Number of subjects: 188
Study 11756368 — intervention group
Group type: COMPARATOR
Intervention: Surgical abortion
Number of subjects: 188
Study 9230252 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (1 mg of nicotine per 100 microL)
Number of subjects: 157
Study 9230252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 9230252 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Number of subjects: 157
Study 7895421 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting with no fluid replacement
Number of subjects: 15
Study 7895421 — intervention group
Group type: COMPARATOR
Intervention: Fasting with salt and water supplementation
Number of subjects: 15
Study 7895421 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting with fluid restriction
Number of subjects: 15
Study 3294614 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril at a dose of 25 mg twice a day
Number of subjects: 74
Study 3294614 — intervention group
Group type: COMPARATOR
Intervention: Nadolol at a dose of 80 mg once a day
Number of subjects: 74
Study 3294614 — intervention group
Group type: COMPARATOR
Intervention: Frusemide at a dose of 25 mg once a day
Number of subjects: 74
Study 31666833 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (TN) and meldonium (ME)
Number of subjects: 98
Study 31666833 — intervention group
Group type: COMPARATOR
Intervention: Control group (GoC)
Number of subjects: 98
Study 29410479 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein and low glycemic index diet (n=38)
Number of subjects: 76
Study 29410479 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=38)
Number of subjects: 76
Study 26926680 — intervention group
Group type: EXPERIMENTAL
Intervention: TriMixDC-MEL plus ipilimumab
Number of subjects: 39
Study 24106141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadazolid (30 mg to 3000 mg, twice daily for 10 days)
Number of subjects: 64
Study 24106141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadazolid (300 mg, single dose)
Number of subjects: 64
Study 24106141 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadazolid (multiple doses)
Number of subjects: 64
Study 24106141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 22800086 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose antioxidant tablets
Number of subjects: 58
Study 22800086 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 58
Study 20849868 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein shake (AUC=37,024±3518nmol/L min)
Number of subjects: 10
Study 20849868 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat shake (AUC=35,977±3562nmol/L min)
Number of subjects: 10
Study 20849868 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate shake (AUC=47,310±3667nmol/L min)
Number of subjects: 10
Study 20849868 — intervention group
Group type: COMPARATOR
Intervention: Water (control condition) (AUC=32,784±1683nmol/L min)
Number of subjects: 10
Study 17826370 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 3941
Study 17826370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3941
Study 15606521 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% cream
Number of subjects: 50
Study 15606521 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 50
Study 11473863 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reversal with neostigmine (50 microg/kg) and glycopyrrolate (10 microg/kg) at 2 min after 1.5 mg/kg rapacuronium
Number of subjects: 119
Study 11473863 — intervention group
Group type: COMPARATOR
Intervention: Late reversal with neostigmine (50 microg/kg) and glycopyrrolate (10 microg/kg) at 25% T1 recovery after 1.5 mg/kg rapacuronium
Number of subjects: 119
Study 11473863 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reversal with neostigmine (50 microg/kg) and glycopyrrolate (10 microg/kg) at 2 min after 2.0 mg/kg rapacuronium
Number of subjects: 119
Study 11473863 — intervention group
Group type: COMPARATOR
Intervention: Late reversal with neostigmine (50 microg/kg) and glycopyrrolate (10 microg/kg) at 25% T1 recovery after 2.0 mg/kg rapacuronium
Number of subjects: 119
Study 9550847 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7825998 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone at 30 mg/kg i.v. for 3 days followed by 20 mg/kg for 4 days
Number of subjects: 8
Study 7825998 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 8
Study 7825998 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone treatment group
Number of subjects: 8
Study 7825998 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone treatment
Number of subjects: 8
Study 3387687 — intervention group
Group type: EXPERIMENTAL
Intervention: Tartrazine (up to 25 mg)
Number of subjects: 156
Study 3387687 — intervention group
Group type: EXPERIMENTAL
Intervention: Tartrazine (50-3,000 mg)
Number of subjects: 156
Study 30203029 — intervention group
Group type: COMPARATOR
Intervention: SMEDS‐EPA
Number of subjects: 80
Study 30203029 — intervention group
Group type: COMPARATOR
Intervention: SMEDS‐DHA
Number of subjects: 80
Study 30203029 — intervention group
Group type: COMPARATOR
Intervention: EE‐EPA
Number of subjects: 80
Study 30203029 — intervention group
Group type: COMPARATOR
Intervention: EE‐DHA
Number of subjects: 80
Study 30203029 — intervention group
Group type: COMPARATOR
Intervention: SMEDS
Number of subjects: 80
Study 28222531 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise with music (ExM)
Number of subjects: 85
Study 28222531 — intervention group
Group type: COMPARATOR
Intervention: Cognitive stimulation (CS)
Number of subjects: 85
Study 26129947 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine manual thrombectomy
Number of subjects: 10732
Study 23324112 — intervention group
Group type: EXPERIMENTAL
Intervention: Group V-CTC (vacuum‐formed retainer in the maxilla and bonded canine‐to‐canine retainer in the mandible)
Number of subjects: 75
Study 23324112 — intervention group
Group type: EXPERIMENTAL
Intervention: Group V-S (vacuum‐formed retainer in the maxilla combined with stripping of the 10 proximal surfaces of the lower mandibular anterior teeth)
Number of subjects: 75
Study 23324112 — intervention group
Group type: EXPERIMENTAL
Intervention: Group P (prefabricated positioner covering the teeth in the maxilla and the mandible)
Number of subjects: 75
Study 20947241 — intervention group
Group type: EXPERIMENTAL
Intervention: 30:2 compression:ventilation ratio
Number of subjects: 42
Study 20947241 — intervention group
Group type: COMPARATOR
Intervention: 15:2 compression:ventilation ratio
Number of subjects: 42
Study 18315686 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 3182
Study 18315686 — intervention group
Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 3182
Study 17111685 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 150
Study 14633567 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia combined with thoracic epidural anesthesia (TEA) (group E, n = 10)
Number of subjects: 20
Study 14633567 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (group G, n = 10)
Number of subjects: 20
Study 11156449 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidectomy
Number of subjects: 119
Study 11156449 — intervention group
Group type: COMPARATOR
Intervention: Conventional open diathermy technique
Number of subjects: 119
Study 9174298 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (3-10 mL of 0.25%-0.5%)
Number of subjects: 8
Study 9174298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8478309 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin (500 mg, two tablets once daily)
Number of subjects: 7437
Study 8478309 — intervention group
Group type: COMPARATOR
Intervention: Comparator antibiotics (1000 mg erythromycin base, 300 mg roxithromycin, 1200 mg miocamycin)
Number of subjects: 7437
Study 8478309 — intervention group
Group type: EXPERIMENTAL
Intervention: Dirithromycin
Number of subjects: 7437
Study 8478309 — intervention group
Group type: COMPARATOR
Intervention: Comparator antibiotics
Number of subjects: 7437
Study 3709640 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg disopyramide i.v.
Number of subjects: 7
Study 3709640 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg atenolol i.v.
Number of subjects: 7
Study 3709640 — intervention group
Group type: EXPERIMENTAL
Intervention: Both disopyramide and atenolol
Number of subjects: 7
Study 3709640 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide and atenolol (combined use)
Number of subjects: 7
Study 31591483 — intervention group
Group type: EXPERIMENTAL
Intervention: High satiety responsive group (HighSR)
Number of subjects: 150
Study 31591483 — intervention group
Group type: EXPERIMENTAL
Intervention: High food responsive group (HighFR)
Number of subjects: 150
Study 31591483 — intervention group
Group type: EXPERIMENTAL
Intervention: High emotional eating group (HighEE)
Number of subjects: 150
Study 29262271 — intervention group
Group type: EXPERIMENTAL
Intervention: C7 nerve transfer plus rehabilitation
Number of subjects: 36
Study 29262271 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation alone
Number of subjects: 36
Study 27073145 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole vaginal tablet 500 mg
Number of subjects: 240
Study 27073145 — intervention group
Group type: COMPARATOR
Intervention: Oral fluconazole 150 mg
Number of subjects: 240
Study 24801283 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg clopidogrel
Number of subjects: 0
Study 24801283 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg prasugrel
Number of subjects: 0
Study 24801283 — intervention group
Group type: EXPERIMENTAL
Intervention: 180 mg ticagrelor
Number of subjects: 0
Study 24801283 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 23102968 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-phage cocktail at a dose of 3×10(9) plaque-forming units
Number of subjects: 15
Study 23102968 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-phage cocktail at a dose of 3×10(7) plaque-forming units
Number of subjects: 15
Study 23102968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 23102968 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-phage cocktail (both doses)
Number of subjects: 15
Study 20233175 — intervention group
Group type: EXPERIMENTAL
Intervention: 'Get Randomised' media campaign (television, radio, newspaper advertising)
Number of subjects: 1040
Study 18613991 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (specialty advice and evidence-based messages regarding medication management for cardiovascular risk)
Number of subjects: 639
Study 18613991 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention, received e-mail with periodic generic information about cardiovascular risk reduction in diabetes)
Number of subjects: 639
Study 18613991 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 639
Study 16182898 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 418
Study 16182898 — intervention group
Group type: COMPARATOR
Intervention: Nitrogen
Number of subjects: 418
Study 11927130 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous unfractionated heparin (UH) administered in two to three subcutaneous doses adjusted to activated partial thromboplastin time (APTT)
Number of subjects: 59
Study 11927130 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparin (LMWH) (dalteparin) administered in a fixed dose of 200 IU/kg body weight in one subcutaneous injection daily
Number of subjects: 59
Study 11927130 — intervention group
Group type: COMPARATOR
Intervention: Both groups (UH and LMWH)
Number of subjects: 59
Study 10440622 — intervention group
Group type: COMPARATOR
Intervention: Skim milk
Number of subjects: 23
Study 10440622 — intervention group
Group type: COMPARATOR
Intervention: High-fat breakfast
Number of subjects: 23
Study 10440622 — intervention group
Group type: COMPARATOR
Intervention: Fasted conditions
Number of subjects: 23
Study 7589047 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine vapour inhaler
Number of subjects: 15
Study 7589047 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 15
Study 2085330 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysate (Solcoseryl)
Number of subjects: 0
Study 2085330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 383851 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 20-1724
Number of subjects: 0
Study 383851 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 383851 — intervention group
Group type: COMPARATOR
Intervention: 0.025% triamcinolone acetonide (intensive occlusive treatment)
Number of subjects: 0
Study 30979042 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Cognitive Behavior Therapy (LI-CBT) mHealth-supported intervention
Number of subjects: 0
Study 30979042 — intervention group
Group type: EXPERIMENTAL
Intervention: WhatsApp usage during the intervention
Number of subjects: 0
Study 30979042 — intervention group
Group type: EXPERIMENTAL
Intervention: LI-CBT intervention at 1-month follow-up
Number of subjects: 0
Study 28326906 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) tablets
Number of subjects: 0
Study 25602615 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional English-as-a-second-language (ESL) instruction
Number of subjects: 155
Study 25602615 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 155
Study 23348400 — intervention group
Group type: EXPERIMENTAL
Intervention: Late parenteral nutrition (PN)
Number of subjects: 280
Study 23348400 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient restriction early during critical illness
Number of subjects: 280
Study 21268101 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium XR 60 mg once daily for 12 weeks
Number of subjects: 1165
Study 21268101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1165
Study 18955519 — intervention group
Group type: COMPARATOR
Intervention: BILR 355 coadministered with 100 mg ritonavir (RTV) at doses of 5 to 50 mg in a polyethylene glycol solution or 50 to 250 mg as tablets, and 150 mg BID coadministered with 100 mg RTV QD or BID.
Number of subjects: 12
Study 18955519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17418559 — intervention group
Group type: EXPERIMENTAL
Intervention: 7‐Keto
Number of subjects: 40
Study 17418559 — intervention group
Group type: EXPERIMENTAL
Intervention: HUM5007
Number of subjects: 40
Study 17418559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16127251 — intervention group
Group type: EXPERIMENTAL
Intervention: SVD-CBF without correction for tracer delay
Number of subjects: 7
Study 16127251 — intervention group
Group type: EXPERIMENTAL
Intervention: SVD-CBF with correction for tracer delay
Number of subjects: 7
Study 16127251 — intervention group
Group type: COMPARATOR
Intervention: PET-CBF
Number of subjects: 7
Study 16127251 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracer delay in white matter
Number of subjects: 7
Study 16127251 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracer delay in gray matter
Number of subjects: 7
Study 11511131 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-report conditions allowing children to monitor and control their answers.
Number of subjects: 3
Study 9242943 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional dialysis using dialyzers with a urea clearance of 170‐180 ml/min
Number of subjects: 195
Study 9242943 — intervention group
Group type: EXPERIMENTAL
Intervention: All hemodialysis treatments
Number of subjects: 195
Study 8333759 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding cows' milk protein during the first three months of life
Number of subjects: 453